A panel of experts agreed that exa-cel, a sickle cell disease gene therapy, was safe enough for clinical use, setting the stage for a potential FDA approval; the United States saw an increase in infant mortality rates for the first time in more than 2 decades; the new antiburnout campaign from the CDC asks leaders to better support health care workers.
Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.
The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer.
The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
Investigators evaluated the utility of the MG Symptoms Patient-Reported Outcome (PRO) within the armamentarium of instruments that currently evaluate myasthenia gravis (MG) severity.
The approval of secukinumab is the second approved biologic to treat hidradenitis suppurativa.
A report published by the Urban Institute estimates that if the 10 Medicaid nonexpansion states were to implement expansions in 2024, Medicaid enrollment would increase by 5 million people, and 2.3 million fewer individuals would be uninsured
No genes were identified in psoriatic patches that were not also mutated in the patient’s unaffected skin area.
The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Anshul Mangal, biotech entrepreneur, attorney, CEO, and founder of Project Farma, discusses how supply chain disruptions and the current cancer drug shortage are affecting patients.
Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
Insurance status is known to be associated with health care access and outcomes, and a recent study found that maternal private insurance is associated with a lower infant mortality rate compared with public Medicaid insurance in the United States.
Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.
Although they cannot address all concerns, on-demand digital health solutions offer personalized support for patients in need of care after normal business hours.
Democratic senators urge private insurers fully cover Opill, an OTC contraceptive pill; providers pursue lawsuit against Arizona's abortion rule; a quarter of US medical students contemplate leaving their studies.
Investigators found that myeloma cells may lose or change targets and subsequently go undetected by these therapies, suggesting that screening for such changes regularly could help guide treatment.
Reduced cost-sharing for asthma medications improved adherence to controller medications among patients with severe asthma.
Federal actuaries have projected what they believe to be health care spending through 2030-2031 in 9 important areas.
On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Patients with a history of retinal artery occlusions were found to have an increased risk of myocardial infarction and death compared with patients who had cataracts.
Patients being unaware of their hepatitis C virus (HCV) infection is preventing the World Health Organization (WHO) from accomplishing its goal of eliminating HCV and hepatitis B virus as public threats by 2030.
Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Investigators hope that ongoing research and addressing disparities can improve equitable access to asthma treatments for all pediatric patients.
Pharmacy workers embark on a multiday strike; Fathers are taking paid family leave to bond with their newborns; the FDA is set to evaluate a pioneering gene therapy for sickle cell disease (SCD).
Leaders from Every Cure and Moonshots for Unicorns highlight their work toward finding treatments for rare diseases currently without a cure.
Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.
Children of all ages with achondroplasia are now included in the expanded Indication, the most common form of skeletal dysplasia leading to disproportionate short stature.
At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with pulmonary arterial hypertension (PAH).
